Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

doses 12 hours apart, the concentration of ANA598 in plasma 12 hours after the second dose was 83 ug/mL, which substantially exceeds the level predicted to display antiviral potency. The data will be presented in a late-breaker poster titled "Results of a Phase I Safety, Tolerability and Pharmacokinetic Study of ANA598, a Non-Nucleoside NS5B Polymerase Inhibitor, in Healthy Volunteers", at 1:00 p.m. PST on Monday, November 3.

ANA598 Preclinical Data at AASLD Meeting

In addition to the results of the Phase I healthy volunteer study, Anadys is presenting additional data on the preclinical profile of ANA598 at the AASLD Meeting on Tuesday, November 4.

-- In a poster titled "In Vitro Studies Demonstrate that Combinations of Antiviral Agents that Include HCV Polymerase Inhibitor ANA598 have the Potential to Overcome Viral Resistance", Anadys will present the results of in vitro studies that show ANA598 to be synergistic with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside polymerase inhibitor PSI-6130 (the active agent of R7128). These studies also show that ANA598 retains activity against mutants known to confer resistance to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors and non-nucleosides that bind at the thumb site. Genotypic mutations resistant to ANA598 will be shown to be fully susceptible to interferon-alpha, telaprevir (VX-950) and PSI-6130. Data will also be presented demonstrating synergy between ANA598 and cytokines induced by ANA773, Anadys' TLR7 agonist oral prodrug, also in development for hepatitis C. These data strongly support the potential for ANA598 to be used in combination with multiple other agents approved or under investigation for hepatitis C.

-- In a poster titled "Antiviral Efficacy of the HCV RNA Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection", Anadys will present data showing that ANA598 exhibits a substantial antivir
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... SEATTLE , Sept. 3, 2015  Omeros Corporation ... filed patent infringement lawsuits against Par Pharmaceutical, Inc. and ... the U.S. District Court for the District of ... District Court for the District of Delaware ... Act for Par,s infringement of three Omeros patents, U.S. ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ... the "Investigation Report on China Tamsulosin Market, ... Compared with other a1- adrenergic receptor blockers, ... and lower risk of urinary tract infections and ... its debut in 1993 in Japan ...
(Date:9/3/2015)... Pharma major Lupin Limited ... (Lupin) has launched its Duloxetine 40 mg Delayed-Release ... generic Duloxetine formulation to become available in 40 ... this new strength to market, as it adds ... flexibility of treatment.      (Photo: ...
Breaking Medicine Technology:Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4China Tamsulosin Market Investigation Report 2015 2Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 2Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 3Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 4
... 30, 2011 Company remains committed to ... R&D pipeline boasts 70 potential medicines in clinical development, including ... at least ten potential new medicines in Phase III by the ... therapeutic areas such as neuroscience, diabetes and oncology, as well as ...
... June 29, 2011 OnCore® Software ... Toolkit works with any eIRB system, including commercial and homegrown ... direction between Clinical Trials Management System (CTMS) and eIRB system. ... timely access to both clinical and regulatory data. ...
Cached Medicine Technology:Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16Forte Research Systems Opens Their OnCore Software Developer Toolkit for Use With Any eIRB System 2Forte Research Systems Opens Their OnCore Software Developer Toolkit for Use With Any eIRB System 3
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... The ... mission control, the surface of a comet, the IceCube observatory at the South Pole, ... way. , The Fall Lecture Series for the world's foremost independently funded research ...
(Date:9/3/2015)... New York, New York (PRWEB) , ... September 03, 2015 , ... ... chief of the Division of Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell ... Medical College. , Dr. Winchell is a nationally renowned expert in care for the ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic Information ... conference, “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” In this Sept. ... and Milliman, will discuss how plan sponsors are adopting bold, innovative strategies to ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ProScrub is a ... back & forth, flicker, repeat, and custom speed effects without the use of keyframes. ... speed of effect. ProScrub tools are perfect complements to energetic video productions. ...
(Date:9/3/2015)... ... September 03, 2015 , ... “Love in Tokyo” an independent romantic comedy film ... Amazon and will be released on DVD early next year, by Maverick ... Itsuka, an actress and singer/songwriter, and Jason London, lead from “Dazed and Confused.” ...
Breaking Medicine News(10 mins):Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 2Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 4Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 5Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2
... (About Euro 46 M),Frutarom Establishes its Position as One of the 10 Largest ... ... Frutarom Continues to Implement Rapid Growth Strategy, HAIFA, Israel, October ... it has signed an agreement to acquire 100% of the share capital of ...
... (October 15, 2007) Patients have on average a ... top-rated hospitals compared with the lowest-rated hospitals across 18 ... Hospital Quality in America Study, issued today by HealthGrades, ... wide variation in the quality of care between the ...
... A new study by Rhode Island Hospital and Brown University ... surgery did not receive the initial psychiatric clearance for the ... of decisions to clear candidates for surgery, and the largest ... and detail the reasons for exclusion. It was published in ...
... created an easy-to-produce material from the stuff of ... bend light in the opposite direction from all ... to significant advances in many areas, including high-speed ... A Princeton-led research team has created an easy-to-produce ...
... other vital organs is critical for survival, experts say, ... flow to the brain and other vital organs is ... emphasize chest compressions over rescue breathing, particularly for heart ... is just two breaths per every 30 chest compressions. ...
... in Support of National Breast ... Cure, DALLAS, Oct. 13 NASCAR drivers Bobby ... Cure at today,s Bank of,America 500 race at Lowe,s ... ) Bobby Labonte,s #43, sponsored by General Mills, ...
Cached Medicine News:Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 2Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 3Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 4Health News:Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors 5Health News:Mortality rates 71 percent lower at top-rated hospitals: HealthGrades 2008 hospital-quality study 2Health News:Mortality rates 71 percent lower at top-rated hospitals: HealthGrades 2008 hospital-quality study 3Health News:1 in 5 bariatric surgery candidates not psychologically cleared for surgery 2Health News:Novel semiconductor structure bends light 'wrong' way -- the right direction for many applications 2Health News:Novel semiconductor structure bends light 'wrong' way -- the right direction for many applications 3Health News:Chest Compressions Key to Revised CPR Guidelines 2Health News:Chest Compressions Key to Revised CPR Guidelines 3Health News:General Mills' #43, M&M's #38 Driving Passionately Pink for the Cure at Lowe's Motor Speedway NASCAR Race 2
... centrifuges -- the world's most popular Microhematocrit ... one reliable, quiet, compact unit. It is ... separate centrifuges!, For your microcentrifuge needs, order ... you with the MicroMB centrifuge, microcentrifuge rotor ...
... spins up to 25,000 x g for quick and ... ease of use. The Model 5417 C is designed ... cold room and can accommodate a variety of microcentrifuge ... Spin up to 16,400 rpm; 25,000 x g ...
... The Model EXD explosion-proof laboratory floor model ... explosion-proof apparatus. EXD is suitable for use ... all divisions; "atmospheres containing gasoline, petroleum, naphtha, ... Adherence to these specifications is so strict ...
... Oven/Shaker rigidly controls the temperature and ... hybridization and washing steps. This facilitates ... nucleic acids and proteins immobilized on ... radioactive and nonradioactive labeling systems supplied ...
Medicine Products: